The comparative activities of azithromycin (AZI) and clarithromycin (CLA) against eight Mycobacterium avium complex (MAC) Azithromycin (AZI) and clarithromycin (CLA) have in vitro activities against Mycobacterium avium complex (MAC) isolates (6, 11). The MICs of AZI and CLA for 90% of isolates tested are 32 and 4 jig/ml, respectively (11). These agents have activities in the beige mouse model of disseminated MAC infection (2, 5, 9). The in vivo activities of these agents against M. avium ATCC 49601 (for which the in vitro MICs of AZI and CLA are 8 and 4 ,ig/ml, respectively) were similar when each drug was administered at 200 mg/kg of body weight daily for 10 days (2). Although AZI and CLA as single agents have promising activities in patients with MAC bacteremia and AIDS (3, 14) , the activities of these agents have not been compared in clinical studies in humans.
Azithromycin (AZI) and clarithromycin (CLA) have in vitro activities against Mycobacterium avium complex (MAC) isolates (6, 11) . The MICs of AZI and CLA for 90% of isolates tested are 32 and 4 jig/ml, respectively (11) . These agents have activities in the beige mouse model of disseminated MAC infection (2, 5, 9) . The in vivo activities of these agents against M. avium ATCC 49601 (for which the in vitro MICs of AZI and CLA are 8 and 4 ,ig/ml, respectively) were similar when each drug was administered at 200 mg/kg of body weight daily for 10 days (2) . Although AZI and CLA as single agents have promising activities in patients with MAC bacteremia and AIDS (3, 14) , the activities of these agents have not been compared in clinical studies in humans.
The purpose of the present study was to compare the in vivo activity of AZI with that of CLA against eight isolates of MAC in the beige mouse model of disseminated infection. In addition, in vitro MICs were measured by the broth dilution method to determine whether the in vitro activities of these agents correlate with their in vivo activities. Analyses of variance and subsequent Tukey honestly significant difference tests indicated that increases in organism cell counts in the spleens between early and late control groups were significant for seven of eight MAC isolates (P < 0.05 for MAC K; P < 0.01 for the remaining six isolates). The increase in cell counts in the spleens between early and late control groups for MAC 101 was not significant (P > 0.05) ( Table 2) .
Organism cell counts in the spleens of mice treated with AZI at either dose or CLA at 200 mg/kg were reduced in comparison with those in the spleens of the early control groups for six of eight isolates (ATCC 49601, MAC K, MAC G, MAC T, MAC R, and MAC E) (P < 0.01). For MAC F, the reduction in organism cell counts seen in the spleens of mice treated with AZI at either dose was significant compared with the counts in the spleens of early controls (P < 0.01), but the reduction seen in the spleens of mice treated with CLA was not significant (P > 0.05). For MAC 101, the reduction in cell counts seen in the spleens of mice treated with AZI at 200 mg/kg was significant compared with the counts in the spleens of early controls (P < 0.01). The reductions in cell counts seen in the spleens of mice treated with AZI at 100 mg/kg or CLA were not significant (P > 0.05). The reductions in cell counts in the spleens of all treated groups compared with the counts in the spleens of late control groups were significant for all eight MAC isolates (P < 0.01).
A dose-related reduction in splenic cell counts between groups receiving AZI at 100 mg/kg and AZI at 200 mg/kg was observed. The reduction in organism cell counts in the spleens between groups receiving AZI at 100 mg/kg and AZI at 200 mg/kg was significant for six of eight isolates (ATCC 49601, MAC K, MAC G, MAC T, MAC R, and MAC E) (P < 0.05 for MAC R; P < 0.01 for the remaining five isolates). The reductions in organism cell counts in the spleens between groups receiving AZI at 100 mg/kg and AZI at 200 mg/kg were not significant for MAC F or MAC 101 (P > 0.05).
AZI at 200 mg/kg was more active than CLA at 200 mg/kg against organisms in the spleens for six of eight MAC isolates (ATCC 49601, MAC K, MAC F, MAC G, MAC T, and MAC E) (P < 0.01). There was no difference in the activities of AZI at 200 mg/kg and CLA at 200 mg/kg against MAC 101 or MAC R (P < 0.05).
Organism counts in lungs. The increases in cell counts between early and late control groups for organisms in the lungs of mice were significant for five of eight MAC isolates (P < 0.01). The increases in organism cell counts in the lungs between early and late control groups for MAC 101, MAC G, and MAC T were not significant (P > 0.05) ( Table 2 ).
Treatment with AZI at 100 mg/kg did not reduce organism cell counts in the lungs compared with the counts in the early control groups for any isolate. Treatment with AZI at 200 mg/kg reduced organism cell counts in the lungs in comparison with those in the lungs of the early control groups only for isolates MAC G and MAC T (P < 0.01). Treatment with CLA at 200 mg/kg reduced organism cell counts in the lungs in comparison with those in the lungs of the early control groups for five of eight isolates (ATCC 49601, MAC G, MAC T, MAC R, and MAC E) (P < 0.01). The reductions in organism cell counts in the lungs seen with CLA at 200 mg/kg in comparison with those in the lungs of early control groups were not significant for the remaining three isolates (P > 0.05). The reduction in organism cell counts in the lungs of all treatment groups in comparison with those in the lungs of late control groups were significant for all MAC isolates except MAC 101. Although a dose-related reduction in organism cell counts in the lungs between groups receiving AZI at 100 mg/kg and AZI at 200 mg/kg was observed, the differences were not significant for any MAC isolate (P > 0.05).
CLA at 200 mg/kg was more active than AZI at 200 mg/kg against organisms in the lungs for three of eight MAC isolates (ATCC 49601, MAC T, and MAC E) (P < 0.05 for MAC T; P < 0.01 for ATCC 49601 and MAC E). The difference between CLA at 200 mg/kg and AZI at 200 mg/kg against organisms in the lungs was not significant for the remaining five isolates (P > 0.05).
DISCUSSION
The in vitro MICs of AZI and CLA for the eight MAC isolates tested in the present study fell into a rather narrow ranges ( Table 1) . Because of the relative lack of variation in in vitro susceptibility, correlation between in vitro susceptibility and in vivo efficacy could not be ascertained with the series of isolates that we used. An alternative approach would be to use isogenic mutants of a single MAC isolate with various levels of in vitro AZI or CLA resistance. These drug-resistant mutants could be studied to determine whether there is a correlation between in vitro activity and efficacy in the murine model. AZI and CLA had activities against each of the eight MAC isolates evaluated in the murine test system. This is in contrast to our earlier comparative studies of newer rifamycins in beige mice. Despite favorable in vitro susceptibility results, rifabutin and rifapentine had activities against organisms in the spleens for only two of five MAC isolates (10) .
AZI and CLA were more active against organisms in the spleens than against those in the lungs, perhaps because of the presence of a larger population of extracellular rather than intracellular organisms in the lungs. AZI at 200 mg/kg was more active than CLA at 200 mg/kg against organisms in the spleens for the majority of the MAC isolates. AZI at 100 mg/kg had activity comparable to that of CLA at 200 mg/kg against organisms in the spleens. CILA at 200 mg/kg was more active than AZI at 200 mg/kg against organisms in the lungs for three of eight isolates; otherwise, CIA at 200 mg/kg had activity comparable to that of AZI at 200 mg/kg against organisms in the lungs.
CILA and AZI are used for the treatment of disseminated MAC infection in people with AIDS (3, 14) ; however, the comparative efficacies of these two agents have not been evaluated in humans. Comparative trials of AZI and CLA in combination with ethambutol and/or rifabutin in patients with disseminated MAC infections will be necessary to determine any clinically significant differences in their efficacies and tolerances in this patient population.
